Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: Pegunigalsidase alfa in Japanese patients with Fabry disease
jRCT2031230079Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Open-label trial of pegunigalsidase alfa in Fabry disease (FD) (3 cohorts), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Incidence of treatment emergent adverse events (TEAEs), Incidence of infusion related reactions (IRRs) and 19 more. Started Aug 2023; status: recruiting.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2031230079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230079.